Who Generates Higher Gross Profit? Merck & Co., Inc. or Perrigo Company plc

Merck's Gross Profit Dominance Over Perrigo: A Decade in Review

__timestampMerck & Co., Inc.Perrigo Company plc
Wednesday, January 1, 2014254690000001447700000
Thursday, January 1, 2015245640000001712400000
Friday, January 1, 2016259160000002051800000
Sunday, January 1, 2017273470000001979500000
Monday, January 1, 2018287850000001831500000
Tuesday, January 1, 2019327280000001773300000
Wednesday, January 1, 2020279000000001815200000
Friday, January 1, 2021350780000001416200000
Saturday, January 1, 2022418720000001455400000
Sunday, January 1, 2023439890000001680400000
Loading chart...

Data in motion

A Tale of Two Giants: Merck & Co., Inc. vs. Perrigo Company plc

In the competitive world of pharmaceuticals, Merck & Co., Inc. and Perrigo Company plc have been key players. Over the past decade, Merck has consistently outperformed Perrigo in terms of gross profit. From 2014 to 2023, Merck's gross profit surged by approximately 73%, peaking in 2023. In contrast, Perrigo's growth was modest, with a peak in 2016 and a slight decline thereafter.

Merck's strategic investments and innovative product lines have propelled its financial success, while Perrigo has faced challenges in maintaining its growth trajectory. By 2023, Merck's gross profit was nearly 26 times that of Perrigo, highlighting the stark contrast in their financial performances. This data underscores the importance of strategic planning and innovation in the pharmaceutical industry, where market dynamics can shift rapidly.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025